| Dr Christine Holzer Mccarty, MD | |
|
713b S Fayetteville St, Asheboro, NC 27203-6405 | |
| (336) 626-0033 | |
| Not Available |
| Full Name | Dr Christine Holzer Mccarty |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 45 Years |
| Location | 713b S Fayetteville St, Asheboro, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437102878 | NPI | - | NPPES |
| 1189U | Other | NC | BCBS NC |
| 87965 | Other | NC | MEDCOST |
| 30340 | Other | NC | PARTNERS MEDICARE |
| 891189U | Medicaid | NC | |
| 7078016 | Other | NC | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 9900601 (North Carolina) | Secondary |
| 207RX0202X | Internal Medicine - Medical Oncology | 9900601 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of The Piedmont Inc | High point, NC | Hospice |
| Moses H. Cone Memorial Hospital, The | Greensboro, NC | Hospital |
| Randolph Hospital | Asheboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Moses H Cone Memorial Hospital Operating Corporation | 6204744600 | 496 |
News Archive
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.
Physicians from leading plastic surgery and dermatology practices report positive results from HIV patients participating in a clinical trial of Radiesse synthetic injectable implant on facial wasting. The trial is intended to demonstrate the safety and effectiveness of this widely used tissue augmentation therapy as a treatment for the facial changes that socially stigmatize many HIV-infected patients.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
› Verified 2 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356372064 PECOS PAC ID: 6204744600 Enrollment ID: O20031204000940 |
News Archive
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.
Physicians from leading plastic surgery and dermatology practices report positive results from HIV patients participating in a clinical trial of Radiesse synthetic injectable implant on facial wasting. The trial is intended to demonstrate the safety and effectiveness of this widely used tissue augmentation therapy as a treatment for the facial changes that socially stigmatize many HIV-infected patients.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
› Verified 2 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.
Physicians from leading plastic surgery and dermatology practices report positive results from HIV patients participating in a clinical trial of Radiesse synthetic injectable implant on facial wasting. The trial is intended to demonstrate the safety and effectiveness of this widely used tissue augmentation therapy as a treatment for the facial changes that socially stigmatize many HIV-infected patients.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christine Holzer Mccarty, MD Po Box 14878, Greensboro, NC 27415-4878 Ph: (336) 547-1877 | Dr Christine Holzer Mccarty, MD 713b S Fayetteville St, Asheboro, NC 27203-6405 Ph: (336) 626-0033 |
News Archive
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.
Physicians from leading plastic surgery and dermatology practices report positive results from HIV patients participating in a clinical trial of Radiesse synthetic injectable implant on facial wasting. The trial is intended to demonstrate the safety and effectiveness of this widely used tissue augmentation therapy as a treatment for the facial changes that socially stigmatize many HIV-infected patients.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
› Verified 2 days ago
Charles S Betts, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1831 N Fayetteville St, Asheboro, NC 27203 Phone: 336-672-1300 Fax: 336-672-3044 | |
Dr. Dequincy Andrew Lewis, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 713 S Fayetteville St, Suite B, Asheboro, NC 27203 Phone: 336-626-0033 | |
Ava M Swayze, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 364 White Oak St, Asheboro, NC 27203 Phone: 336-830-9192 | |
Dr. Brian J Munley, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 542 White Oak St, Asheboro, NC 27203 Phone: 336-610-3720 | |
Dr. Shiv Kumar Harsh, M. D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 542 White Oak St, Asheboro, NC 27203 Phone: 336-629-4176 Fax: 336-626-6604 | |
Mrs. Nina Uppin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 237-a N. Fayetteville Street, Asheboro, NC 27203 Phone: 336-625-3248 Fax: 336-625-6629 | |
Patricia Ann Pierce, ANP Internal Medicine Medicare: Medicare Enrolled Practice Location: 138 Dublin Square Rd Ste B, Asheboro, NC 27203 Phone: 336-610-1300 Fax: 336-625-2163 |